Pemphigoid diseases are a group of well defined autoimmune disorders that are
characterised by autoantibodies against structural proteins of the dermal–epidermal junction …

Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects
elderly individuals. Increase in incidence rates in the past decades has been attributed to …

Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
blistering disease of the skin and mucous membranes. This disease typically affects the …

Background Several European countries recently developed international diagnostic and
management guidelines for pemphigus, which have been instrumental in the …

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease
in Western countries, and typically affects the elderly. BP is immunologically characterized …

Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of
the skin and mucous membranes. This disease typically affects the elderly and presents with …

Importance Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP).
However, its effectiveness and safety have yet to be confirmed in a large-scale study …

Bullous pemphigoid (BP) is a type 2 inflammation-and immunity-driven skin disease, yet a
comprehensive understanding of the immune landscape, particularly immune-stromal …

Bullous pemphigoid (BP) is a major autoimmune blistering skin disorder, in which a majority
of the autoantibodies (autoAbs) target the juxtamembranous extracellular noncollagenous …

Background Bullous pemphigoid (BP) is an autoimmune blistering disorder that
predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are …